RhumbLine Advisers
TARS icon

RhumbLine Advisers’s Tarsus Pharmaceuticals TARS Stock Holding History

RhumbLine Advisers’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
52,718
+5,760
+12% +$368K ﹤0.01% 1672
2026
Q1 		$3.29M Sell
46,958
-122
-0.3% -$8.52K ﹤0.01% 1605
2025
Q4 		$3.85M Sell
47,080
-9,443
-17% -$705K ﹤0.01% 1533
2025
Q3 		$3.36M Sell
56,523
-1,127
-2% -$55.5K ﹤0.01% 1627
2025
Q2 		$2.34M Buy
57,650
+5,968
+12% +$269K ﹤0.01% 1805
2025
Q1 		$2.65M Buy
51,682
+2,148
+4% +$106K ﹤0.01% 1671
2024
Q4 		$2.74M Buy
49,534
+1,019
+2% +$46.3K ﹤0.01% 1721
2024
Q3 		$1.6M Sell
48,515
-1,145
-2% -$32.2K ﹤0.01% 2025
2024
Q2 		$1.35M Buy
49,660
+6,070
+14% +$204K ﹤0.01% 2084
2024
Q1 		$1.58M Buy
43,590
+1,970
+5% +$57.9K ﹤0.01% 2020
2023
Q4 		$843K Buy
41,620
+5,614
+16% +$93.7K ﹤0.01% 2354
2023
Q3 		$640K Buy
36,006
+544
+2% +$9.63K ﹤0.01% 2459
2023
Q2 		$641K Buy
35,462
+6,944
+24% +$110K ﹤0.01% 2536
2023
Q1 		$358K Buy
28,518
+924
+3% +$13.5K ﹤0.01% 2559
2022
Q4 		$405K Buy
27,594
+296
+1% +$4.9K ﹤0.01% 2562
2022
Q3 		$467K Buy
27,298
+1,536
+6% +$24.4K ﹤0.01% 2528
2022
Q2 		$376K Buy
+25,762
New +$387K ﹤0.01% 2635

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's TARS Position: Q2 2026 in Review

RhumbLine Advisers increased its Tarsus Pharmaceuticals (TARS) stake by 12% in Q2 2026, buying an estimated $368K and bringing the position to 52,718 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

RhumbLine Advisers first reported a position in TARS in Q2 2022 and has held it in 17 quarters since. The position peaked at $3.85M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • RhumbLine Advisers held 52,718 shares of Tarsus Pharmaceuticals worth $3.32M as of Q2 2026.
  • RhumbLine Advisers bought 5,760 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $368K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1672 holding.
  • RhumbLine Advisers first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • RhumbLine Advisers's Tarsus Pharmaceuticals position peaked at $3.85M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.